A collaborative study conducted by researchers at the University of Michigan and the University of California San Diego has identified…
Read More
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels
The persistence of estrogen receptor-positive (ER+) breast cancer remains one of the most formidable challenges in modern oncology, as patients…
Read More
Anixa Biosciences Secures Key Patent for Breast Cancer Vaccine Technology in South Korea, Expanding Global Intellectual Property Portfolio
Anixa Biosciences has achieved a significant milestone in its quest to develop a preventive vaccine for breast cancer, securing a…
Read More
Breast milk nutrient shapes immune development in mice
A significant new study from the University of Chicago (UChicago; IL, USA), published in the prestigious journal Science, has illuminated…
Read More
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels.
This seminal research, conducted by a collaborative team from the University of Michigan and the University of California San Diego,…
Read More
FDA Grants Priority Review to Roche’s Giredestrant for Early-Stage Breast Cancer, Signaling Potential Paradigm Shift in Adjuvant Therapy
The US Food and Drug Administration (FDA) has accepted priority review of the new drug application (NDA) for Roche’s investigational…
Read More
Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels.
A collaborative research effort between the University of Michigan and the University of California San Diego has identified a critical…
Read More
AbbVie Secures FDA Approval for Ultra-Rare Blood Cancer Therapy, While AstraZeneca Faces Delay for Breast Cancer Drug
The U.S. Food and Drug Administration (FDA) has recently issued a significant approval for AbbVie’s antibody-drug conjugate (ADC) targeting blastic…
Read More
How breast cancer cells survive in bone marrow after remission
The Challenge of Estrogen Receptor-Positive Breast Cancer Estrogen receptor-positive (ER+) breast cancer represents approximately 70% to 80% of all breast…
Read More
Datroway Receives FDA Approval for Metastatic Triple-Negative Breast Cancer, Marking a Significant Advancement in Targeted Therapy
The US Food and Drug Administration (FDA) has granted a pivotal approval for Datroway (datopotamab deruxtecan), a novel antibody-drug conjugate…
Read More
